Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XELOX + QL1706 + tyrosine kinase inhibitor
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
XELOX + QL1706 + tyrosine kinase inhibitor is a combination therapy regimen being evaluated for the treatment of advanced hepatocellular carcinoma (HCC). The regimen consists of the XELOX chemotherapy backbone (oxaliplatin and capecitabine), the bifunctional anti-PD-1/CTLA-4 antibody QL1706 (also known as iparomlimab/tuononlimab), and a tyrosine kinase inhibitor (TKI), specifically either lenvatinib or regorafenib. QL1706 is a MabPair bifunctional antibody that simultaneously blocks the Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) immune checkpoints, aiming to enhance the anti-tumor immune response. The TKI component (lenvatinib or regorafenib) provides anti-angiogenic and anti-proliferative effects by inhibiting multiple receptor tyrosine kinases, including VEGFR and FGFR. The XELOX component provides cytotoxic chemotherapy. This combination is part of the HCC-SIGHT platform trial led by Fudan University to identify effective second-line therapies for HCC.
- Brand names
- XelodaEloxatinLenvimaStivarga
- Other names
- XELOX + QL1706 + TKIOxaliplatin + Capecitabine + QL1706 + LenvatinibOxaliplatin + Capecitabine + QL1706 + Regorafenib
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAFGFR1 (Fibroblast growth factor receptor 1)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on XELOX + QL1706 + tyrosine kinase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XELOX + QL1706 + tyrosine kinase inhibitor.